The director of TIS Cherrell Hirst previously directed Peplin Biotech (asx code PEP) .
It was poorly managed and wasted years trying to get trials done for its skin cancer cream when these could have been concluded quickly.
There were repeated capital raisings and endless dilutions of shares. Eventually it was taken over by a foreign firm and all the local shareholders lost millions on what should have been a sure fire winner.
Seeing the same thing here for TIS good technology ,poor management i have sold out before the endless capital raisings and probable takeover . Almost certainly with no premium.
Good luck but I fear history repeating.
TIS Price at posting:
4.3¢ Sentiment: Sell Disclosure: Not Held
